ERBB2 and neoplasm: To explore if the subgroup of patients evaluated in the HER2 study was representative of the whole population entered in the clinical trial, the main patient and tumour characteristics in this subgroup (731 cases) were compared with those of the subgroup without HER2 assessment (483 cases).